ClinicalTrials.gg
Active, not recruitingNCT05871021PRIDEUpdated Sep 29, 2026

Protective VEGF Inhibition for Isotoxic Dose Escalation in Glioblastoma

A Phase 2 interventional study of Dose escalation of radiation dose beyond the therapeutic standard in Glioblastoma, sponsored by University Hospital Tuebingen. Active, not recruiting at 9 sites in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by University Hospital Tuebingen · Phase 2, Interventional, and Treatment

How we know

Updated Sep 29, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
107
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 133 studies in Glioblastoma with a site in Germany — 25 open to participants now, 37 under way, 8 of them phase 3. Glioblastoma · Germany.

Enrollment
57th of 112
107 · median 108
Started
2024
with 7 others
Phase 2
27 of 133
4 open now
Primary completion
2028-12
later than 25 of 36 live
Registered
112th of 133
by date
Lead sponsor
4 of 133
University Hospital Tuebingen

Among the 133 studies in Glioblastoma with a site in Germany, this one is the 57th largest by enrollment of the 112 interventional ones that give a count, is one of 8 that started in 2024, is one of 27 in phase 2, reaches primary completion later than 25 of the 36 other live ones, and was the 112th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

25 of the 133 studies in Glioblastoma with a site in Germany are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 133 studies in Glioblastoma with a site in Germany, or all of them as a file.
02

Study summary

Glioblastoma is the most aggressive brain tumor and often recurs locally despite intensive treatment. Standard chemoradiotherapy with 60 Gy may not be sufficient to control the tumor, and dose escalation seems to be warranted, but causes more toxicity. To address this, the multicentric PRIDE trial employs two cycles of bevacizumab to achieve dose escalation isotoxically. The goal is improved survival without significantly increasing side effects. The study uses a simultaneous integrated boost with a total dose of 75 Gy in 2.5 Gy per fraction.

03

Conditions studied

  • Glioblastoma

Browse trials for

Keywords

  • Dose escalation
  • bevacizumab
  • VEGF inhibition
  • FET PET
  • VMAT
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • IDH wild-type, MGMT unmethylated glioblastoma patients
  • Age ≥18 and ≤70 years, smoking or non-smoking, of any ethnic origin
  • 0-2
  • >1500/µl, counts >100.000/µl, > 8 g/dl, Serum creatinine \<1.5-fold (ULN), , or ALT \<2.5-fold ULN unless attributed to anticonvulsants, Alkaline phosphatase \<2.5-fold ULN
  • Adequate
  • Serum creatinine ≤ 1.5 x ULN AND patients with urine dipstick for proteinuria \< 2+. Patients with ≥ 2+ proteinuria on dipstick urinalysis at baseline should show urine protein to creatinine ratio ≤ 1

Exclusion criteria

Exclusion Criteria:

  • Evidence of significant hemorrhage on postoperative MRI of the brain. Patients with asymptomatic, minor hemosiderin deposition, resolving postsurgical hemorrhagic changes, or punctate intratumoral hemorrhage (e.g., related to or surgery) are not excluded
  • Subjects on any drug suspected to interfere with bevacizumab at the time of study inclusion
  • Immuno-compromised patients, including known seropositivity for (HIV)
  • Known to any component of the drugs or (allergy to or other intolerability of bevacizumab or excipients)
  • Any other significant medical illness or medically significant laboratory finding that would, in the investigator's judgement, make the patient inappropriate for this study, or would increase the risk associated with the patients' participation in the study
  • Incapability to undergo MRI
  • Prior treatment with bevacizumab for any indication
  • and/or hypersensitivity to bevacizumab or its excipients. For details check the Summary of Product Characteristics Aybintio®
  • Significant cardiovascular disease defined as congestive heart failure ( Class II, III, IV), unstable angina pectoris, or myocardial infarction within 6 months prior to enrolment
  • Inadequately controlled hypertension (defined as a blood pressure of > 150 mmHg systolic and/or >100 mmHg diastolic on medication), or any prior history of hypertensive crisis or hypertensive encephalopathy
  • History of cerebrovascular events within 6 months prior to enrolment. This includes ischemic stroke or . Small, clinically silent perioperative ischemic changes are not exclusionary.
  • Significant vascular disease (e.g. aortic aneurysm, aortic dissection or recent peripheral arterial thrombosis) within 6 months prior to enrolment
  • Evidence or history of recurrent thromboembolism (> 1 episode of deep venous thrombosis / peripheral embolism) during the past 2 years
  • Evidence of bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation)
  • Chronic daily intake of aspirin > 325 mg/day or clopidogrel > 75 mg /day
  • History of intracranial abscess within 6 months prior to inclusion
  • History of abdominal or tracheo-oesophageal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrolment
  • History of ≥ grade 2 hemoptysis according to NCI-CTC criteria within 1 month prior to inclusion
  • Serious non-healing wound, ulcer or bone fracture
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
107 participants (actual)

Study arms

  • Experimental
    75 Gy with two cycles of bevacizumab

    Radiation: Dose escalation of radiation dose beyond the therapeutic standard

Interventions

  • RadiationDose escalation of radiation dose beyond the therapeutic standard

    Dose escalation to 75 Gy with concomitant radioprotectant bevacizumab

    Also known as: bevacizumab

06

What researchers measure

Primary outcomes

  1. OS

    Overall Survival

    Time frame: Date of study inclusion (informed consent) to death or end of F/U

Secondary outcomes

  1. Safety and tolerability

    Safety and tolerability of dose escalation with bevacizumab according to CTCAE v5.0

    Time frame: Date of study inclusion (informed consent) to death or end of F/U

  2. PFS-6

    6 months rate of progression-free survival

    Time frame: 6 months after the date of study inclusion (informed consent)

  3. PFS

    Progression-free survival

    Time frame: Date of study inclusion (informed consent) to death or progression

  4. QoL

    Quality of life as determined by EORTC QLQ-C30/QLQ-BN 20

    Time frame: Date of study inclusion (informed consent) to death or end of F/U

  5. Cognitive function

    Cognitive function determined by standard test batteries

    Time frame: Date of study inclusion (informed consent) to death or end of F/U

  6. Exploratory objective

    Validation of prognostic 4-miRNA signature-based risk score

    Time frame: Date of study inclusion (informed consent) to death or end of F/U

07

Study locations

9 sites
  • Department of Radiation Oncology, University Hospital Augsburg
    Augsburg, Germany
  • Department of Radiation Oncology, University Hospital Köln
    Cologne, Germany
  • Department of Radiation Oncology, University Hospital Frankfurt
    Frankfurt, Germany
  • Department of Radiation Oncology, University Hospital Freiburg
    Freiburg im Breisgau, Germany
  • Department of Radiation Oncology, University Hospital Leipzig
    Leipzig, Germany
  • Department of Radiation Oncology, Medical Faculty Mannheim
    Mannheim, Germany
  • Department of Radiation Oncology, University Hospital, LMU Munich
    Munich, Germany
  • Department of Neurology, University Hospital Regensburg
    Regensburg, Germany
  • Department of Radiation Oncology
    Tübingen, 72076, Germany
08

References and documents

Publications

  • Maier SH, Schonecker S, Anagnostatou V, Garny S, Nitschmann A, Fleischmann DF, Buttner M, Kaul D, Imhoff D, Fokas E, Seidel C, Hau P, Kolbl O, Popp I, Grosu AL, Haussmann J, Budach W, Celik E, Kahl KH, Hoffmann E, Tabatabai G, Paulsen F, Holzgreve A, Albert NL, Mansmann U, Corradini S, Belka C, Niyazi M, Bodensohn R. Dummy run for planning of isotoxic dose-escalated radiation therapy for glioblastoma used in the PRIDE trial (NOA-28; ARO-2024-01; AG-NRO-06). Clin Transl Radiat Oncol. 2024 May 4;47:100790. doi: 10.1016/j.ctro.2024.100790. eCollection 2024 Jul. PubMed 38765202 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Dec 2028, 56 months after the start.

Of 197 non-industry phase 2 interventional studies under Glioblastoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's planned 56 months is close to that.

Counting every sponsor, half of 248 studies reached it within 55 months; a quarter within 40 and three quarters within 87.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 29, 2026: primary completion Apr 2028 → Dec 2028 and completion Jul 2028 → Apr 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2023
First posted
May 23, 2023
StartActual
Apr 10, 2024
Primary completionEst.
Dec 31, 2028was Apr 2028
CompletionEst.
Apr 15, 2029was Jul 2028
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Sep 29, 2026
Primary completion
Apr 10, 2028→Dec 31, 2028
Sep 29, 2026
Study completion
Jul 10, 2028→Apr 15, 2029
Sep 29, 2026
Enrollment
146 (estimated)→107 (actual)
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Recruiting→Active, not recruiting
    Primary completion Apr 10, 2028→Dec 31, 2028
    Study completion Jul 10, 2028→Apr 15, 2029
    Enrollment 146 (estimated)→107 (actual)
    + 4 other changes: identifiers, verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05871021
Responsible party
Sponsor
First posted
May 23, 2023
Start date
Apr 10, 2024
Primary completion
Dec 31, 2028 (estimated)
Completion
Apr 15, 2029 (estimated)
Last update
Sep 29, 2026

Study contacts

Maximilian Niyazi, Prof. Dr.
principal investigator · University Hospital Tuebingen, Department of Radiation Oncology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion